Safety of Otic Medications During Pregnancy

General Principles for Medication Use in Pregnancy

• The American Academy of Allergy, Asthma, and Immunology recommends that FDA pregnancy categories help guide medication selection, with Category A and B medications generally considered safer than Categories C, D, or X 1, 2
• The American College of Obstetricians and Gynecologists suggests using the lowest effective dose for the shortest duration necessary 1

Recommended Otic Medications During Pregnancy

• The American Academy of Otolaryngology recommends corticosteroid-containing otic preparations, such as budesonide, fluticasone, and mometasone, as safe options during pregnancy 1, 2, 3
• Budesonide (Category B) has the most safety data and may be preferred when initiating treatment during pregnancy, according to the American College of Allergy, Asthma, and Immunology 1, 2

Medications to Avoid or Use with Caution

• The American College of Obstetricians and Gynecologists advises avoiding oral decongestants during pregnancy, especially when combined with acetaminophen or salicylates, due to increased risk of congenital malformations 1, 5
• First-generation antihistamines should be avoided due to their sedative and anticholinergic properties, as recommended by the American Academy of Otolaryngology 6

Management Algorithm for Ear Conditions During Pregnancy

• The American Academy of Otolaryngology recommends using topical preparations with established safety profiles, such as budesonide, fluticasone, or mometasone-based products, as a first-line approach 1, 3
• For infectious conditions, penicillin or cephalosporin-based otic preparations are recommended, according to the American College of Obstetricians and Gynecologists 2, 4

Common Pitfalls and Considerations

• The American College of Allergy, Asthma, and Immunology notes that assuming all topical medications have equivalent safety profiles during pregnancy is incorrect, and safety data varies significantly between agents 5
• The first trimester carries the highest risk for medication-induced teratogenicity, and whenever possible, delay non-urgent treatments until after this period, as recommended by the American Academy of Otolaryngology 2, 3